Tag Archives: Crohn’s disease

Fresenius Kabi Secures Global Rights to PB016 Vedolizumab Biosimilar from Polpharma Biologics

(IN BRIEF) Fresenius Kabi has licensed rights from Polpharma Biologics to commercialize the vedolizumab biosimilar candidate PB016 globally—except in the Middle East and North Africa—once approved. Vedolizumab treats Crohn’s disease and ulcerative colitis, and PB016 references Takeda’s Entyvio®. The transaction … Read the full press release

New Research Links Mitochondrial Dysfunction to Crohn’s Disease, Offering Hope for Targeted Treatments

(IN BRIEF) Researchers at the Technical University of Munich have found that mitochondrial dysfunction in the intestines can trigger Crohn’s disease symptoms by disrupting the gut microbiome. This groundbreaking discovery establishes a direct link between defective mitochondria and both tissue … Read the full press release

Sanofi and Teva Collaborate on Inflammatory Bowel Disease Treatment, TEV’574, in $1.5 Billion Deal

(IN BRIEF) Sanofi and Teva Pharmaceuticals have announced a collaboration to co-develop and co-commercialize TEV’574, a promising asset currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn’s Disease, both forms of inflammatory bowel disease (IBD). … Read the full press release

Milestone for the diagnosis of inflammatory bowel disease

Clinicians at the University Hospital Erlangen show how a new laser-based imaging technique termed MSOT can detect inflammation more accurately than current non-invasive diagnostic procedures and thereby help reduce the burden to patients MUNICH, 30-Mar-2017 — /EuropaWire/ — Ulcerative colitis … Read the full press release